Resistance of ERBB2 KD mutants to trastuzumab

Stable Identifier
R-HSA-9665233
Type
Pathway
Species
Homo sapiens
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this pathway in the Pathway Browser

This pathway describes resistance of ERBB2 KD mutants to therapeutic antibody trastuzumab (herceptin) (Bose et al. 2013, Rexer et al. 2013, Hanker et al. 2017, Nagano et al. 2018).

Literature References
PubMed ID Title Journal Year
28274957 An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer

Hanker, AB, Brewer, MR, Sheehan, JH, Koch, JP, Sliwoski, GR, Nagy, R, Lanman, R, Berger, MF, Hyman, DM, Solit, DB, He, J, Miller, V, Cutler, RE, Lalani, AS, Cross, D, Lovly, CM, Meiler, J, Arteaga, CL

Cancer Discov 2017
29967253 High-Throughput Functional Evaluation of Variants of Unknown Significance in ERBB2

Nagano, M, Kohsaka, S, Ueno, T, Kojima, S, Saka, K, Iwase, H, Kawazu, M, Mano, H

Clin. Cancer Res. 2018
23948973 Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2

Rexer, BN, Ghosh, R, Narasanna, A, Estrada, MV, Chakrabarty, A, Song, Y, Engelman, JA, Arteaga, CL

Clin. Cancer Res. 2013
23220880 Activating HER2 mutations in HER2 gene amplification negative breast cancer

Bose, R, Kavuri, SM, Searleman, AC, Shen, W, Shen, D, Koboldt, DC, Monsey, J, Goel, N, Aronson, AB, Li, S, Ma, CX, Ding, L, Mardis, ER, Ellis, MJ

Cancer Discov 2013
Participants
Participant Of
Disease
Name Identifier Synonyms
cancer 162 malignant tumor, malignant neoplasm, primary cancer
Authored
Reviewed
Created
Cite Us!